FDA-CLEARED DIGNICAP® SCALP COOLING SYSTEM COMES TO  THREE MORE U.S. CANCER TREATMENT CENTERS

DigniCap® Scalp Cooling System Helps Cancer Centers Provide Patients with
an Alternative to One of Breast Cancer’s Most Devastating Side Effects
Lund, Sweden—April 18, 2016—Dignitana AB, a world leader in medical scalp
-cooling technology, announced today that the DigniCap® scalp cooling system,
which was recently cleared by the FDA to effectively reduce the likelihood of
chemotherapy-induced hair loss in women with breast cancer, is now also
available at cancer treatment centers in Tampa and Palm Beach, Florida and
Battle Creek, Michigan. Since FDA clearance in December, thirteen U.S. medical
centers have begun the process of introducing the DigniCap® scalp cooling system
to their patients. Agreements with dozens more are currently in motion.

The DigniCap® system is the first and only scalp cooling device to complete
rigorous FDA clinical trials in the U.S., where seven out of ten patients with
early-stage breast cancer kept at least 50% of their hair.

The DigniCap® scalp cooling system features a patented tight-fitting silicone
cooling cap that is placed directly on the head, and an outer neoprene cap that
insulates and secures the silicone cap. The cooling cap is connected to a
cooling and control unit with touch screen prompts. A liquid coolant circulates
throughout the silicone cap, delivering consistent and controlled cooling to all
areas of the scalp. The cap is fitted to the head, and the temperature of the
scalp is lowered, resulting in vasoconstriction with reduced delivery of
chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to
decreased intra follicular metabolic rate. These factors together reduce the
risk of chemotherapy-induced hair loss.

Bronson Battle Creek Cancer Care
Center (https://www.bronsonhealth.com/locations/bronson-battle-creek-cancer-care
-center/) in Battle Creek, Michigan and two leading cancer centers in Tampa and
Palm Beach, Florida are now in the process of installing the DigniCap® system
and incorporating treatments into their patients’ regimens.

“We are very excited to be moving so quickly to fulfill U.S. medical center
requests for the DigniCap® scalp cooling system, and proud that these
prestigious cancer centers have signed Dignitana as a partner to help provide
their patients with an alternative to the emotionally traumatic side effect of
chemotherapy related hair loss,” said Jan Richardsson, Chief Executive Officer
of Dignitana. “After years of clinical trials, we are pleased to be able to
offer physicians and medical centers in the United States a scientifically
proven procedure that infusion centers can readily incorporate into their
treatment protocols.”
Media Contact:

Jan Richardsson

CEO, Dignitana AB (publ)

Ph  +46 (0)46 16 30 92

E jan.richardsson@dignitana.com
About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the
medical cooling device DigniCap®. Dignitana is continuously researching and
developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq
First North stock exchange and has appointed Erik Penser Bank as Certified
Adviser. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that
offers cancer patients the ability to keep their hair during chemotherapy.
DigniCap® is developed to provide continuous cooling with high efficacy, safety
and acceptable patient comfort.